Allergan Acquires Chase Pharmaceuticals
Pharama Tech | November 23, 2016
Allergan announced that it has completed the acquisition of Chase Pharmaceuticals Corporation, a biopharmaceutical company specializing in the development of improved treatments for neurodegenerative disorders including Alzheimer's disease. Allergan has paid an upfront fee of $125 million (subject to certain adjustments) to Chase. There will be additional potential regulatory and sales milestone payments related to Chase's lead compound, CPC-201, and certain backup compounds.